This occurs because appetite returns to pre-treatment levels and the body's metabolic adaptations to weight loss persist, making weight maintenance challenging without continued intervention
One of the most misunderstood parts of the GLP-1 experience is this: eating less doesn't automatically mean your metabolism cooperates
Treatments are personalised based on BMI, medical history, and weight loss goals to support safe, sustainable, and evidence-based long-term results
However, losing those side effects can also make it easier for your appetite to return
As a naturally occurring peptide fragment, BPC-157 also lacks strong patent protection, which has likely reduced commercial incentive to fund the trials needed for FDA approval
The retatrutide research compound Velora supplies as GLP-3 RT is sold strictly for laboratory research use, not for human consumption, veterinary use, or in vivo use in any species